OR7C2 Antibody

What is OR7C2 and what cellular functions does it perform?

OR7C2 (olfactory receptor family 7 subfamily C member 2) is a G-protein coupled receptor 1 family member that functions as an odorant receptor. In humans, the canonical protein has 312 amino acid residues with a molecular weight of approximately 35 kDa (34.7-35.3 kDa) . It is localized to the cell membrane as a multi-pass membrane protein and is involved in the regulation of transcription and signal transduction pathways, particularly those related to olfactory sensing. OR7C2 interacts with odorant molecules in the nose to initiate neuronal responses that trigger smell perception . The protein undergoes post-translational modifications, notably glycosylation, which can affect its functionality and detection in experimental assays .

What are the common synonyms and alternative names for OR7C2?

When searching literature and antibody databases, it's important to recognize the various designations for OR7C2:

These alternative designations are particularly important when performing comprehensive literature searches or when comparing antibodies from different manufacturers .

What are the primary applications for OR7C2 antibodies in research?

The most validated applications for OR7C2 antibodies include:

• Western Blot (WB): Most commercially available OR7C2 antibodies are validated for WB applications, typically using dilutions ranging from 1:500 to 1:2000 .

• Enzyme-Linked Immunosorbent Assay (ELISA): Another common application, with typical dilutions around 1:10000 .

• Immunohistochemistry (IHC): Some antibodies are specifically validated for IHC, particularly for paraffin-embedded tissues, with recommended dilutions of 1:50 to 1:200 .

• Immunocytochemistry (ICC) and Immunofluorescence (IF): Less common but available with specific antibody clones .

When selecting an antibody for a particular application, researchers should prioritize those with validation data specific to their experimental system and application .

How should researchers evaluate the specificity of OR7C2 antibodies?

Evaluating antibody specificity for OR7C2 requires a multi-faceted approach:

• Epitope Analysis: Review the immunogen sequence used to generate the antibody. For example, some OR7C2 antibodies are generated against synthetic peptides from specific regions (aa 198-247 or aa 286-319) . Sequence alignment tools should be used to ensure the epitope is unique to OR7C2 and doesn't cross-react with closely related olfactory receptors.

• Validation Controls:

  • Positive Controls: Use cell lines known to express OR7C2 (e.g., SW480, PANC-1, MCF-7, and HeLa have been documented) .

  • Negative Controls: Include blocking peptide experiments where the antibody is pre-incubated with the immunizing peptide. True-specific binding should be abolished in these conditions .

  • Knockout/Knockdown Validation: When available, use OR7C2 knockout or knockdown samples to confirm specificity.

• Cross-Reactivity Testing: For antibodies claiming reactivity to human, mouse, and rat OR7C2, sequence homology should be verified, and species-specific validation data should be reviewed .

• Multiple Detection Methods: Confirm target detection using at least two different techniques (e.g., WB plus IHC or ICC) .

What are the critical parameters for optimizing Western blot protocols with OR7C2 antibodies?

Optimizing Western blot protocols for OR7C2 detection requires attention to several parameters:

• Sample Preparation:

  • Use whole cell lysates with adequate protein concentration (typically 20 μg per lane) .

  • Include protease inhibitors to prevent degradation of the target protein.

  • Consider membrane protein enrichment protocols for improved detection.

• Denaturation Conditions:

  • As a membrane protein, OR7C2 may require specific denaturation conditions to prevent aggregation.

  • Avoid excessive heating which can cause membrane protein aggregation.

• Transfer Considerations:

  • Use PVDF membranes rather than nitrocellulose for better retention of hydrophobic membrane proteins.

  • Consider longer transfer times or specialized buffers for efficient transfer of membrane proteins.

• Blocking and Antibody Incubation:

  • Test different blocking agents (BSA vs. non-fat milk).

  • Optimize primary antibody dilution (typically 1:500-1:2000) .

  • Incubate primary antibody at 4°C overnight for better results.

• Detection:

  • Use appropriate secondary antibodies (e.g., Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution) .

  • Consider enhanced chemiluminescence detection systems for optimal sensitivity.

• Predicted Band Size:

  • Expect a band at approximately 35 kDa, which corresponds to the calculated molecular weight of OR7C2 .

  • Be aware that post-translational modifications, particularly glycosylation, may affect the observed molecular weight.

How can researchers distinguish between closely related olfactory receptor family members when using antibodies?

Distinguishing between closely related olfactory receptor family members presents significant challenges due to sequence homology. Advanced researchers should implement the following strategies:

• Epitope Mapping Analysis:

  • Perform detailed sequence alignments of the immunogen peptide against all olfactory receptor family members.

  • Select antibodies raised against the most divergent regions between OR7C2 and related proteins (particularly OR7C3 and other subfamily members).

  • Consider custom antibody development targeting unique regions if commercial options lack specificity.

• Orthogonal Validation Approaches:

  • Combine antibody-based detection with mRNA expression analysis (qPCR with highly specific primers).

  • Implement mass spectrometry-based validation for unambiguous protein identification.

  • Use CRISPR/Cas9 gene editing to create specific knockout models for validation.

• Multi-antibody Strategy:

  • Deploy antibodies from different vendors targeting distinct epitopes of OR7C2.

  • Compare staining/detection patterns to establish consensus results.

  • If discrepancies arise, further investigate with additional techniques.

• Recombinant Expression Controls:

  • Generate tagged recombinant versions of OR7C2 and closely related family members.

  • Test antibody specificity against these defined proteins to assess cross-reactivity profiles quantitatively.

What factors contribute to inconsistent results when using OR7C2 antibodies, and how can these be addressed?

Inconsistent results with OR7C2 antibodies can stem from multiple sources. Advanced troubleshooting should address:

• Protein Extraction Efficiency:

  • OR7C2, being a membrane protein, requires specialized extraction methods.

  • Implement comparative extraction using different detergents (RIPA, NP-40, Triton X-100, SDS).

  • Consider sequential extraction protocols to optimize membrane protein solubilization.

  • Monitor extraction efficiency with membrane protein markers.

• Post-translational Modification Variability:

  • Glycosylation patterns may vary between cell types and physiological conditions.

  • Implement deglycosylation treatments (PNGase F) to establish if modifications affect antibody recognition.

  • Compare results across multiple cell lines to establish consistent detection patterns.

• Fixation and Sample Processing Effects:

  • For IHC/ICC applications, fixation can significantly impact epitope accessibility.

  • Compare results between different fixation methods (paraformaldehyde, methanol, acetone).

  • Implement antigen retrieval optimization (pH series, retrieval duration).

  • Quantify signal-to-noise ratios under different processing conditions.

• Experimental Variables Control:

  • Maintain consistent experimental conditions (temperature, incubation times).

  • Implement internal loading controls appropriate for membrane proteins.

  • Use standardized positive control samples across experiments.

  • Consider using automated systems for enhanced reproducibility.

• Antibody Stability and Storage Effects:

  • Prepare small aliquots to minimize freeze-thaw cycles.

  • Monitor antibody performance over time with standard samples.

  • Implement quality control measures for antibody validation before each critical experiment.

How can OR7C2 antibodies be effectively used in multiplexed imaging or flow cytometry applications?

Implementing OR7C2 antibodies in advanced multiplexed applications requires sophisticated approaches:

• Panel Design Considerations:

  • Evaluate spectral overlap carefully when selecting fluorophores for OR7C2 co-staining.

  • Consider antibody species origin and isotype to avoid secondary antibody cross-reactivity.

  • Prioritize directly conjugated antibodies when available to reduce background.

  • Validate each antibody individually before combining into multiplexed panels.

• Signal Optimization Strategies:

  • Implement titration experiments to determine optimal antibody concentration.

  • Consider signal amplification systems (tyramide signal amplification) for low-abundance expression.

  • Use appropriate compensation controls for flow cytometry applications.

  • Implement spectral unmixing algorithms for highly multiplexed imaging.

• Advanced Validation Approaches:

  • Perform fluorescence minus one (FMO) controls for flow cytometry panels.

  • Implement sequential staining protocols to minimize cross-reactivity.

  • Use computational approaches to quantify colocalization in imaging applications.

  • Consider cyclic immunofluorescence methods for highly multiplexed tissue imaging.

• Data Analysis Considerations:

  • Implement machine learning algorithms for unbiased population identification.

  • Use dimensionality reduction techniques (tSNE, UMAP) for high-parameter data visualization.

  • Quantify coexpression patterns using correlation analysis.

  • Develop robust gating strategies for flow cytometry applications.

How can OR7C2 antibodies be utilized in single-cell analysis techniques?

Integrating OR7C2 antibodies into single-cell analysis requires specialized approaches:

• Single-Cell Protein Analysis:

  • Implement mass cytometry (CyTOF) using metal-conjugated OR7C2 antibodies for high-dimensional analysis.

  • Consider CITE-seq (Cellular Indexing of Transcriptomes and Epitopes by Sequencing) approaches to correlate OR7C2 protein expression with transcriptomic profiles at single-cell resolution.

  • Optimize antibody concentrations specifically for drop-based or well-based single-cell protein assays.

• Spatial Analysis Integration:

  • Implement OR7C2 antibodies in multiplexed spatial transcriptomics workflows.

  • Optimize protocols for tissue clearing techniques when performing whole-mount staining.

  • Develop computational approaches to integrate spatial and expression data.

• Methodological Considerations:

  • Validate antibodies specifically for single-cell applications, which may require higher sensitivity than bulk assays.

  • Implement appropriate single-cell controls, including spike-in standards.

  • Develop specialized fixation protocols that maintain epitope accessibility while enabling single-cell isolation.

  • Monitor batch effects carefully and implement computational correction methods.

What are the considerations for using OR7C2 antibodies in functional studies of olfactory signaling?

When employing OR7C2 antibodies for functional olfactory research:

• Receptor Trafficking Analysis:

  • Implement pulse-chase experiments with surface labeling to track receptor internalization.

  • Use OR7C2 antibodies in conjunction with endosomal markers to monitor trafficking dynamics.

  • Consider live-cell imaging approaches with non-permeabilizing staining protocols.

• Signaling Complex Analysis:

  • Utilize proximity ligation assays (PLA) to detect interactions between OR7C2 and downstream signaling components.

  • Implement co-immunoprecipitation protocols optimized for membrane protein complexes.

  • Consider cross-linking approaches to stabilize transient interactions.

• Functional Response Correlation:

  • Combine OR7C2 immunostaining with calcium imaging to correlate receptor expression with functional responses.

  • Implement simultaneous electrophysiological recording and immunofluorescence approaches.

  • Develop quantitative image analysis pipelines to correlate receptor expression levels with functional outputs.

• Advanced Tissue Analysis:

  • Optimize protocols for whole-mount olfactory epithelium staining.

  • Implement tissue clearing techniques compatible with immunostaining.

  • Consider expansion microscopy approaches for improved spatial resolution.

How should researchers approach validation when using OR7C2 antibodies in tissues or cell types with low expression levels?

Detecting low abundance OR7C2 expression requires sophisticated validation:

• Enhanced Detection Approaches:

  • Implement tyramide signal amplification (TSA) to enhance detection sensitivity.

  • Consider RNAscope in situ hybridization as a complementary approach to validate protein detection.

  • Use ultrasensitive detection systems (e.g., Quantum dots, enzyme-mediated amplification).

  • Consider proximity extension assays for improved sensitivity in protein detection.

• Rigorous Control Implementation:

  • Include tissue-matched negative controls (e.g., olfactory epithelium from appropriate knockout models).

  • Implement competition assays with immunizing peptides to confirm specificity.

  • Use multiple antibody clones targeting different epitopes to confirm expression patterns.

  • Quantify signal-to-background ratios and establish objective detection thresholds.

• Cross-Platform Validation:

  • Correlate antibody staining with mRNA expression data.

  • Implement laser capture microdissection followed by qPCR to validate expression in specific cellular regions showing antibody staining.

  • Consider mass spectrometry-based targeted proteomics as an orthogonal validation approach.

• Quantitative Analysis Framework:

  • Develop rigorous image analysis pipelines to distinguish true signal from background.

  • Implement statistical approaches appropriate for low-abundance detection.

  • Consider Bayesian statistical frameworks for improved sensitivity in detection.

  • Document all analysis parameters to ensure reproducibility.

How should researchers interpret contradictory findings when comparing data generated using different OR7C2 antibodies?

When faced with contradictory results from different OR7C2 antibodies:

• Systematic Comparison Framework:

  • Create a structured comparison table documenting all relevant variables (antibody clone, immunogen, host, applications, validation data).

  • Analyze epitope locations relative to protein domains and potential post-translational modifications.

  • Evaluate the rigor of validation for each antibody based on published literature and manufacturer data.

  • Consider the biological context of each study and whether different protein isoforms or modifications might be detected.

• Technical Resolution Strategies:

  • Design experiments using orthogonal detection methods not reliant on antibodies.

  • Implement genetic approaches (CRISPR/Cas9 knockout, siRNA knockdown) to establish true expression patterns.

  • Conduct side-by-side comparisons under identical experimental conditions.

  • Consider whether different antibodies might be detecting different conformational states of the receptor.

• Analytical Considerations:

  • Evaluate the quantification methods used in different studies.

  • Assess statistical approaches and determine if differences might be due to analysis rather than biology.

  • Implement blinded analysis to eliminate bias in interpretation.

  • Consider developing mathematical models to reconcile apparently contradictory data.

What standards should be implemented to ensure reproducibility in OR7C2 antibody-based research?

To enhance reproducibility in OR7C2 research:

• Comprehensive Reporting Standards:

  • Document complete antibody information (catalog number, lot number, dilution, incubation conditions).

  • Report all sample preparation details, including fixation parameters and antigen retrieval methods.

  • Provide raw images alongside processed data.

  • Document image acquisition parameters (exposure times, gain settings, threshold determinations).

• Validation Framework Implementation:

  • Adopt structured validation approaches as outlined in the antibody validation guidelines.

  • Implement minimum validation requirements specific to each application.

  • Include application-specific positive and negative controls in each experiment.

  • Validate antibodies in the specific experimental context in which they will be used.

• Quantitative Analysis Standardization:

  • Develop standard operating procedures for image analysis.

  • Implement automated analysis workflows to reduce subjective interpretation.

  • Use appropriate statistical approaches and report effect sizes alongside p-values.

  • Consider pre-registering experimental designs and analysis plans for major studies.

• Data Sharing Practices:

  • Deposit raw data in appropriate repositories.

  • Share detailed protocols through protocol repositories.

  • Consider open notebook approaches for enhanced transparency.

  • Implement version control for analysis code and share through public repositories.

How might new antibody engineering technologies improve specificity and utility of OR7C2 antibodies?

Emerging antibody technologies offer promising improvements for OR7C2 research:

• Advanced Recombinant Antibody Approaches:

  • Single-chain variable fragments (scFvs) optimized for membrane protein recognition.

  • Nanobodies (VHH antibodies) with enhanced accessibility to structurally constrained epitopes.

  • Bispecific antibodies targeting OR7C2 alongside confirmatory markers.

  • Affimers and other non-antibody scaffold proteins with high specificity for challenging epitopes.

• Genetic Fusion Strategies:

  • CRISPR knock-in approaches to tag endogenous OR7C2 with small epitope tags.

  • Split-protein complementation systems for detecting OR7C2 in specific cellular compartments.

  • Proximity-dependent labeling approaches (BioID, APEX) to map OR7C2 interactomes.

  • Optogenetic or chemogenetic fusion proteins to enable functional manipulation alongside detection.

• Enhanced Screening Technologies:

  • Implementation of phage display with synthetic libraries optimized for membrane protein recognition.

  • High-throughput specificity screening against all olfactory receptor family members.

  • Single B-cell antibody sequencing to identify highly specific clones.

  • Structural biology-guided antibody engineering for enhanced specificity.

What are the emerging applications of OR7C2 antibodies in understanding olfactory system development and pathology?

Novel research directions for OR7C2 antibodies include:

• Developmental Biology Applications:

  • Tracking OR7C2 expression during olfactory system development.

  • Correlating receptor expression with axon targeting in the olfactory bulb.

  • Investigating the role of OR7C2 in neuronal specification and circuit formation.

  • Studying receptor expression in regeneration after olfactory injury.

• Pathological Investigations:

  • Analyzing OR7C2 expression changes in anosmia and hyposmia conditions.

  • Investigating potential ectopic expression in neurodegenerative disorders.

  • Exploring receptor function in aging-related olfactory decline.

  • Studying potential roles in unexplored conditions like long COVID-associated olfactory dysfunction.

• Translational Research Opportunities:

  • Developing diagnostic approaches based on receptor expression patterns.

  • Exploring OR7C2 as a potential therapeutic target for olfactory disorders.

  • Investigating correlations between receptor polymorphisms and functional outcomes.

  • Studying population-level variations in receptor expression and function.

• Technological Integration:

  • Combining OR7C2 antibodies with organoid models of the olfactory epithelium.

  • Implementing high-content screening approaches to identify modulators of receptor function.

  • Developing biosensor applications based on olfactory receptor activity.

  • Exploring OR7C2 function in non-canonical tissues beyond the olfactory system.